Charles W. Tran

Charles W. Tran

Auto-generated profile, based on publicly available information

Charles W. Tran

Genentech, South San Francisco, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 December 2024 in Nature Cancer
Verified
Journal Article
Open access
PDF file
KNKatherine Nutsch
Katherine Nutsch
KBKarl L. Banta
Karl L. Banta
TWThomas D. Wu
Thomas D. Wu
CTCharles W. Tran
Charles W. Tran
SMStephanie Mittman
Stephanie Mittman
IMIra Mellman
Ira Mellman
Blockade of immune checkpoints PD-1 and TIGIT has demonstrated activity in mouse tumor models and human patients with cancer. Although these coinhibitory receptors can restrict signaling in CD8+ T cells by regulating their associated co-stimulatory receptors CD28 and CD226, the functional consequences of combining PD-1 and TIGIT blockade remain poorly characterized. In mouse tumor models, we show that combination blockade elicited CD226-driven clonal expansion of tumor antigen-specific CD8+ T cells. The expanded clones emerged from a population of stem-like cells in draining lymph nodes, entering the blood as a previously unidentified single-phenotype, multiclonal population. Upon reaching the tumor, these transiting cells expanded further and differentiated into effector or exhausted T cells, with combination blockade restricting entry into the exhaustion pathway by favoring co-stimulation. Thus, PD-1 and TIGIT inhibition helps shape the repertoire of tumor-reactive CD8+ T cells in draining lymph nodes and determines their immunological fate in the tumor to enhance therapeutic benefit. Analysis of clinical trial samples suggests a similar mechanism may also occur in patients with cancer.

3 October 2016 in Nature Cell Biology
Verified
Journal Article
Closed access
WZWeiyue Zheng
Weiyue Zheng
MUMasataka Umitsu
Masataka Umitsu
IJIshaan Jagan
Ishaan Jagan
CTCharles W. Tran
Charles W. Tran
NINoboru Ishiyama
Noboru Ishiyama
SMSenthil K. Muthuswamy
Senthil K. Muthuswamy

15 December 2017 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
CTCharles W. Tran
Charles W. Tran
SSSamuel D. Saibil
Samuel D. Saibil
TBThierry Le Bihan
Thierry Le Bihan
SHSara R. Hamilton
Sara R. Hamilton
KLKarl S. Lang
Karl S. Lang
POPamela S. Ohashi
Pamela S. Ohashi
The decision between T cell activation and tolerance is governed by the spatial and temporal integration of diverse molecular signals and events occurring downstream of TCR and costimulatory or coinhibitory receptor engagement. The PI3K–protein kinase B (PKB; also known as Akt) signaling pathway is a central axis in mediating proximal signaling events of TCR and CD28 engagement in T cells. Perturbation of the PI3K–PKB pathway, or the loss of negative regulators of T cell activation, such as the E3 ubiquitin ligase Cbl-b, have been reported to lead to increased susceptibility to autoimmunity. In this study, we further examined the molecular pathway linking PKB and Cbl-b in murine models. Our data show that the protein kinase GSK-3, one of the first targets identified for PKB, catalyzes two previously unreported phosphorylation events at Ser476 and Ser480 of Cbl-b. GSK-3 inactivation by PKB abrogates phosphorylation of Cbl-b at these two sites and results in reduced Cbl-b protein levels. We further show that constitutive activation of PKB in vivo results in a loss of tolerance that is mediated through the downregulation of Cbl-b. Altogether, these data indicate that the PI3K–PKB–GSK-3 pathway is a novel regulatory axis that is important for controlling the decision between T cell activation and tolerance via Cbl-b.

17 January 2025 in Nature Cancer
Verified
Journal Article
Open access
PDF file
KNKatherine Nutsch
Katherine Nutsch
KBKarl L. Banta
Karl L. Banta
TWThomas D. Wu
Thomas D. Wu
CTCharles W. Tran
Charles W. Tran
SMStephanie Mittman
Stephanie Mittman
IMIra Mellman
Ira Mellman

15 June 2022 in Cancer Research
Verified
Journal Article
Open access
WLWilliam Weijia Lu
William Weijia Lu
JBJames Byers
James Byers
CTCharles W. Tran
Charles W. Tran
MMMichal Mass
Michal Mass
TSTanu Shenoy
Tanu Shenoy
SMStefanie Mandl
Stefanie Mandl
PACT Pharma has developed a robust single-step, targeted, non-viral method for the manufacturing of personalized adoptive cells therapies for the treatment of solid cancers (NCT03970382). For this, we insert and express a neoepitope-specific T cell receptor (neoTCR) from the endogenous locus while simultaneously abolishing the expression of endogenous TCR. This results in neoTCR-specific T cells in which neoTCR expression is naturally regulated and not impeded by competition for CD3 by the endogenous TCR. We furthermore designed a system to additionally express CD8 coreceptor along with the neoTCR on the same RNA transcript from the native TCR promoter. Both methods, currently in clinical testing, allow for the timely generation of several billion T cells expressing neoTCRs using our GMP cell manufacturing procedure. Nevertheless, the suppressive nature of some tumor microenvironments may require cells engineered with further modifications for long lasting therapeutic outcomes in certain patients. Here we describe how the flexibility of a non-viral system allows for additional complex modifications in a single step. First, we demonstrate an additional gene knock-out in the TGFBR2 gene with simultaneous TCR replacement, making the engineered cells resistant to the immunosuppressive effects of TGF-β while still maintaining neoepitope-specific recognition of the tumor. Second, we demonstrate knock-down in addition to TCR replacement. For some targets, reduction of gene expression may be favored over complete knock-out. Accordingly, we have designed an shRNA expression construct that can efficiently knock-down transcript levels of a given gene in cells expressing the neoTCR without the generation of additional double-stranded breaks, allowing for enhanced T cell function in the absence of additional genomic breaks. Third, we demonstrate a non-viral knock-in strategy to express transgenes with transcriptional regulation independent from the neoTCR. This strategy generates a product from which two genes, the neoTCR plus an additional transgene regulated by its own promoter, can be precision genome engineered into the same cell using homology directed templates that far exceed the size limitations of AAV. This technology can be successfully applied for the expression of intracellular, secreted, and membrane-bound proteins as well as proteins expressed only during the activated T cell state. In conclusion, our single-step non-viral precision genome engineering technology is highly versatile with the ability to knock-out, knock-down, knock-in, and precisely regulate additional genes in a single step. These modifications have the potential to expand the applicability of T cell drug products and are broadly applicable to a variety of other cellular therapies and research models. Citation Format: William Lu, James Byers, Charles W. Tran, Michal Mass, Tanu Shenoy, Shirley Sun, Kyle Jacoby, Stefanie Mandl. Non-viral gene editing enables multiplex single-step precision genome engineering for adoptive cell therapies [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 2827.

15 June 2022 in Cancer Research
Verified
Journal Article
Open access
CTCharles W. Tran
Charles W. Tran
KLKayla Lee
Kayla Lee
BPBhamini Purandare
Bhamini Purandare
JBJames Byers
James Byers
MDMichael M. Dubreuil
Michael M. Dubreuil
BSBarbara Sennino
Barbara Sennino
Personalized autologous TCR-T cell therapies targeting neoepitopes (neoE) derived from tumor-specific mutations are a compelling approach for the treatment of patients with solid tumors. Using the ultra-sensitive imPACT Isolation Technology®, antigen-experienced, neoE-specific CD8 T cells are captured from the blood of patients with solid cancers followed by cloning of the cognate, neoE-specific, MHC class I-restricted T cell receptors (neoTCRs). DNA-mediated (non-viral) precision genome engineering technology is then used to engineer autologous CD8 and CD4 T cells to express the neoTCR. We have further built upon this platform to modify neoTCR-T cells to address potential sources for tumor immune evasion. The versatility of this single-step gene editing platform is demonstrated here by the presentation of a neoTCR T cell product with knockout of endogenous TCRα and TCRβ and the simultaneous expression of a neoTCR with CD8 co-receptor (CD8coR) from the same expression cassette along with knockout of TGFβ receptor 2 (TGFBR2). We have previously shown that CD8coR expression augments the activity of CD4 T cells engineered to express MHC class I restricted neoTCRs, by increasing CD4 neoTCR T cell helper and effector function. TGFβ is known to promote tumor growth, metastasis, and epithelial to mesenchymal transition (EMT) and to inhibit effector immune responses while promoting fibrosis and the differentiation of inhibitory cell types such as regulatory T cells. TGFβ is expressed by many tumor types and high TGFβ expression is associated with worse prognosis for several cancer subtypes including colorectal, lung and glioblastoma. TGFBR2 is a critical mediator of TGFβ signaling, resulting in potent, inhibitory effects on T cell function. Our data show that simultaneous ablation of TGFBR2 signaling and expression of CD8coR was achieved with high efficiency, resulting in fully functional CD8 and CD4 neoTCR-T cells. Deletion of TGFBR2 with or without CD8coR expression, together with the expression of a neoE-targeted TCR preserved T cell effector function in the presence of inhibitory concentrations of TGFβ. Importantly, the combination of TGFBR2 knockout and CD8coR expression resulted in additive benefits, providing proof-of-concept for modifying two orthogonal features to improve neoTCR T cell function. Altogether, these results demonstrate the applicability of this versatile, precision genome engineering platform technology to yield enhanced, next-generation neoTCR-T cell therapies to expand the potential for clinical benefit in persons with solid cancers. Citation Format: Charles W. Tran, Kayla Lee, Bhamini Purandare, James Byers, Michael M. Dubreuil, William Lu, Michal Mass, Kyle Jacoby, Stefanie J. Mandl, Barbara Sennino. Non-viral precision genome engineering enables personalized adoptive neoTCR T cell therapy for cancer including multiple additional edits that improve the activity of neoTCR T cells by enhancing CD4 T cell antigen sensitivity and conferring resistance to TGFβ [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 2829.